The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
KRAS mutation status and toxicity of cetuximab, paclitaxel, cisplatin, and concurrent radiation in Chinese patients with locally advanced esophageal squamous cell carcinoma: An open-label, multicenter, phase II study.
J. Yu
No relevant relationships to disclose
X. Meng
No relevant relationships to disclose
J. h. Wang
No relevant relationships to disclose
X. Sun
No relevant relationships to disclose
L. Wang
No relevant relationships to disclose
M. Ye
No relevant relationships to disclose
P. b. Feng
No relevant relationships to disclose
G. y. Zhu
No relevant relationships to disclose
Y. Lu
No relevant relationships to disclose
S. c. Zhu
No relevant relationships to disclose